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Abstract
Bisphosphonates (BP),were initially used in industry and later as a drug due to their great affinity to osseous tissue, 
because of their powerful antiresorptive effect as a treatment in various osteopathies, such as osteoporosis, Paget 
disease or hypercalcemia associated with some malignant tumors, as myeloma or breast cancer. 
They are administered orally or intravenously, and although well tolerated, the most frequent side effects are gastro-
intestinal, in addition to osteonecrosis when they are administered via endovenous.
The aim of this work has been to evaluate the existing publications in accredited scientific literature on biphosphonates 
and their action mechanism and the relationship with the appearance of osteonecrosis of the jaws.
Although the mechanism by which osteonecrosis of the jaws develops is not known exactly, there seems to be influence 
by osteoclast inhibiton, antiangiogenic action, an inhibitory effect on the cellular cycle by the keratinocytes, as well 
as, reinforcement of the chemiotoxic action in oncological patients treated with other drugs.
Clinically, it ranges from a non-specificity of symptoms to lesions such as osteomyelitis with necrosis and osseous 
sequesters that may be accompanied by fetor ex oris, with the appearance of many Actinomyces contaminated le-
sions.
As for published antecedents on osteonecrosis due to bisphosphonate treatment found until 2006:  46.5% had a pre-
vious diagnosis of multiple myeloma; 38.8% were patients with metastatic breast cancer; 6.2% patients of metastatic 
prostate cancer; 4.1% suffered from osteoporosis; 3.5% from other metastatic diseases and 0.8% had Paget disease.  
The drugs that seem to have the highest incidence of osteochemionecrosis are: zoledronate, pamidronate, alendronate, 
risendronate and ibandronate, from the greatest to the least.  Additionally, the risk of osteonecrosis being produced 
is accumulative and may reach 21% in the third year of intravenous bisphosphonate use.  
Key words: Osteonecrosis, necrosis due to phosphorus, bisphosphonates, diphosphonates, myeloma, breast cancer, me-
tastatic cancer, Osteoporosis.
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Introduction
Bisphosphonates (BP), synthesized in the mid 19th cen-
tury by German chemists, were initially used in industry 
due to their capacity to prevent the deposit of calcium 
carbonate, which made them specially useful in avoiding 
the deposit of  calcium salt incrustation in piping and 
pipelines.  Later it was shown that they had great affinity 
with osseous tissue, where they inhibited the conversion of 
amorphous calcium phosphate in hydroxyapatite and they 
reduced the dissolution speed of the latter (1, 2).  From 
the chemical viewpoint, bisphosphonates are analogous 
pyrophosphate structures in which central oxygen has 
been replaced by carbon, which makes theses structures 
have a low bioavailability and facilitates their binding to 
hydroxyapatite osseous crystals. (2)
The first clinical applications of these drugs, at the end 
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of  the 70s, were due to their great affinity to calcium 
phosphate and they were used to perform osseous gamma-
graphies with Tc99m. They were also used as toothpaste 
ingredients, given their anti-tartar and anti-plaque effects. 
But, doubtless it is their powerful anti-resorptive effect 
which has permitted them to become the treatment of 
choice for various osteopathies in which there is excessi-
ve bone resorption, as are osteoporosis, Paget disease or 
hypercalcemia associated with some malignant tumors 
such as myeloma or breast cancer (1, 2, 3).
Administered orally (OA) or intravenously (IV), they are 
usually well tolerated, but the most frequent side effects 
are gastrointestinal, although in recent years the existence 
of oseonecrosis of the jaws has also been described when 
these drugs are administered via endovenous. 
There is similarity between osteonecrosis induced by bis-
phosphonates and the historical entity of “mandibular 
necrosis by phosphorus”.   Phosphorous industry workers 
suffered severe oral ulcers with great pain, nauseating 
odor, necrosis with osseous sequesters that were worse-
ned following dental extraction, and high mortality due 
to infections.  These disorders were also observed in the 
20th century in missile industry workers due to contact 
with white phosphorous, and in the watch industry due to 
making luminescent watch faces, until protection measures 
changed in these work areas (1).
Material and Method
The aim of this work has been the bibliographical search 
in MEDLINE, PubMED, and Cochrane Register of con-
trolled Trials between 1996 and 2006 by using the MeSH 
and the terms:  Osteonecrosis, necrosis by phosphorous, 
bisphosphonates, diphosphonates, Osteoporosis, myelo-
ma, breast cancer, metastatic cancer.
Noteworthy of special attention have been the series of 
cases with patients of osteonecrosis of the jaws associated 
with bisphosphonates and also the descriptions of 1 or 2 
isolated cases (5, 9, 14, 15).
Chemical composition
Bisphosphonates have a chemical composition similar 
to pyrophosphates, endogenous regulators of  osseous 
mineralization and similar effects.  The difference is in 
the bond of the 2 phosphate groups, which in the case of 
bisphophonates are joined by phosphoethers (P-C-P) and 
in pyrophosphates by phosphoanhydrides (P-O-P). This 
bond makes them more resistant to pyrophosphatase and 
to hydrolysis in acid conditions (1, 2). The central ring 
is essential for bonding the osseous hydroxyapatite and 
the lateral chains are variable, and they increase the anti-
resorptive power of the drug and may be of two types: 
a teminal amino chain or a cyclic nitrogen chain (R1 or 
R2) (Figure 1). 
There are two families of these drugs (Table 1):
1.- Those containing nitrogen:   
-Alendronate (Fosamax ®, MSD)
-Risedronate  (Actonel®, Sanofi-Aventis; Acrel®, Vita 
Científica)
-Pamidronate (Aredia ®, Novartis)
-Zoledronate (Zometa®, Novartis)
-Ibandronate (Boniva®, Roche)
 
2.- Those not containing nitrogen:  
-Etidronate (Difosfen®, Rubio; Osteum® , Viñas)
-Tiludronate (Skelide®,Sanofi-Aventis) fos®, Schering)
- Action mechanism and clinical application
Biphosphonates (BP), powerful inhibitors of osteoclastic 
activity, have a rather short average lifespan in blood, 
between 30 minutes and 2 hours, but once they are incor-
porated into bone, they can remain there for up to 12 years 
without deteriorating (1,3). The excretion of the drugs is 
carried out renally without metabolic alteration. 
BP structure determines their bone binding, their power 
and their intracellular effects.  The oldest and least power-
ful BPs, such as etidronate, clodronate and tiludronate, the 
so called first generation BP, are captured by osteoclasts 
and converted into ATP toxic analogues. Nevertheless, 
aminobisphosphonates (N-BP) act by means of pharne-
sildisphosphate synthase inhibition (FPP-synthase), an 
enzyme involved in cholesterol synthesis from mevalo-
nate.  The latter blocks a collateral pathway that controls 
protein geranyl-geranylation, which leads to inactivation 
of GTPases and interference in the signal tranmission 
Fig. 1. Chemical structure.
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of  some cytokines, with the consequent inhibition of 
osteoclastic activity.  Apoptosis of the osteoclasts is also 
induced, but, unlike what occurs with first generation 
BP, the apoptosis does not constitute a necessary step in 
resorption inhibition (2).
The capacity of BP to inhibit osteoclastic activity, and the 
consequent reduction in osseous turnover, has been used to 
treat various osseous diseases that are characterized by an 
increase in remodeling (Figure 2).  It has been demonstra-
ted that biphosphonates increase osseous mineral density 
and reduce fractures in women with post-menopausal 
osteoporosis.  These drugs are also efficient in preventing 
bone mass loss caused by aging, hypoestrogenism and the 
use of glucocorticoids.  Their usefulness has also been 
shown in the treatment of other processes such as Paget 
disease, fibrous displasia, osteogenesis imperfecta, hete-
rotopic ossifications and tumoral hypercalcemia.  Finally, 
it has recently been pointed out that BP may exercise an 
anti-tumoral effect by hindering the development of os-
seous metastasis (2, 3, 8). Aminobisphosphonates favor 
tumoral cell apoptosis and inhibit the binding of the same 
to the intracellular matriz, therefore hindering turmoral 
invasion (4, 8).  They also possess a certain anti-angiogenic 
capacity, which would reinforce their anti-tumoral activity 
(1, 3).
The main limitation of oral bisphosphonates is their poor 
oral absorption (<1%) and their adverse effects on the di-
gestive tract, above all esophagal irritation.  Furthermore, 
oral administration guidelines are inconvenient for many 
patients, and it becomes imposible to carry them out on 
patients confined to bed transitorily or for prolonged 
periods,thus some compounds have been developed that 
may be administered intravenously.  They are usually well 
tolerated, although on occasions flu-like manifestations 
and transitory hypocalcemia are observed.  It is also advi-
sable to monitor plasma creatinine, since an adjustment of 
the dosis or the administration interval may be required in 
the case of renal insufficiency.  Moreover, intravenous BP 
administration is the form that has most often been asso-
ciated with the development of osteonecrosis (5, 6, 8, 13) 
(See Table 1 with doses and forms of administration). 
Pathogenesis of osteonecrosis
Although the mechanism by which osteonecrosis of the 
jaws develops is not known exactly, the cause is believed 
to be constant exposure to crevicular fluid components 
by means of  the periodontal space.  The inflamation 
habitually existing there ,requires increased osseous tur-
nover in order to heal, as happens following a periodontal 
abscess, caries with pulpal affectation or exodoncy.   The 
inflamation itself  favors cytokine and RANKL release 
whcih act by stimulating resorption (3).
In edentulous patients with badly adapted prostheses, 
chronic gum and underlying osseous crest irritation could 
Name Doses Via Administration N-BP Appoved by FDA
Ethidronate 400 mg Oral Intermittent No 1977
Clodronate
800 mg
300 mg
Oral
IV
Daily
Intermittent
No
Not approved in USA; 
Yes in U.E.
Tiludronate 200mg Oral Intermittent No 1997
Pamidronate 30 a 90 mg IV Intermittent Yes 1991
Alendronate
10 mg
70 mg
Oral
Oral
Daily
Weekly
Yes 1995
Risedronate
5 mg
35 mg
Oral
Oral
Daily
Weekly
Yes 1998
Zoledronate 4-5 mg IV Intermittent Yes 2001
Ibandronate
2,5 mg
150 mg
3 mg
Oral
Oral
IV
Daily
Monthly
Intermittent
Yes 2003-2005-2006
Table 1. Formula, doses, administration vias. ( N-BP=  Nitrogenated Bisphosphonates)
Fig. 2. Bone remodeling.
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also favor the development of oral inflamation with an 
increase in turnover and osteonecrosis.  The area most 
susceptible to suffering this oseochemionecrosis is the 
milohioidea crest and in general, the posterior lingual 
mandibular region.  At times there is some coexisting torus 
mandibularis which continuously damages the periostio 
and mucous membranes.  The decrease in bone replace-
ment induced by the bisphosphonates reduces the pheno-
menon of bone repair, thus favoring the development of 
areas of sequester due to osteomyelitis and osteonecrosis 
(2, 5). Likewise, the anti-angiogenic property strengthens 
the isquemic effects found in the area. 
Bisphosphonates also produce an inhibitory effect on the 
keratinocyte cellular cycle, which hinders the habitual 
mucous repair mechanisms (2, 5, 6).
The accummulative effect of all these actions causes con-
tinuous damage to osseous repair when faced with any 
minimal injury (5).
Another added factor in oncological patients is the ad-
ministration of other substances such as corticoids and 
chemiotherapies that alter inflamation mechanisms, and 
on being anti-angiogenic to many of them, they reinforce 
the chemiotoxic action of bisphosphonates (2, 3, 7).
- Clinical injuries and histology
At times the onset is non-specific; the patient notices 
certain discomfort around a tooth or simply a mucosa 
ulceration, with a greater or lesser degree of pain and 
inflamation.  The injuries end up as osteomyelitis with 
necrosis and osseous sequester that may fistulate the skin 
and be accompanied by accute fetor ex oris (3).
Cases of paraesthesia of the 5th pair mandible ramus have 
been described, or even total anaesthesia if  the necrotic 
lesions’ affectation reached the inferior dental canal (9).
Many lesions seem contaminated following the microbio-
logical study with Actinomyces (2, 5, 10, 11) but it must be 
taken into account that this bacteria habitually colonizes 
the oral cavity.  
Although histologically the necrosis is similar to that 
observed in osteoradionecrosis, in the last one alternates 
dead areas with residual nests of living bone.  There are 
inflammatory infiltration and fibrosis in the medular 
spaces in both cases.  Regarding blood vessel obliteration, 
this is greater in osteoradionecrosis (10, 22).
A pseudo-rodent ulcer transformation is also observed 
instead of necrotic bone (10).
In initial phases, radiology is usually rather inspecific, with 
the observation of widening of the periodontal ligament 
indistiguishible from periodontal infection.  Subsequently 
badly defined radiotransparent lesions appeared which were 
accompanied by mandibular fracture in some cases (3).
Risk factors associated with osteochemionecrosis due to 
bisphosphonates are diverse. Firstly, there is the influence 
of the type, doses and administration via of these drugs. 
Most cases have been described in cancer patients who re-
ceive high doses of bisphosphonates (mainly zolendronate 
and pamidronate) intravenously.  In this sense it should 
be pointed out that the doses used in oncological patients 
are 12 times higher that those used in osteoporosis.  Ne-
vertheless, some cases have also been described in women 
with postmenopausic osteoporosis who received treatment 
with oral aminobisphosphonates (10 mg of alendronate 
daily or 2.5 mg of ibandronate daily) (12).
In a review published by Shane in May 2006 (3), a small 
number of  cases was seen of  osteonecrosis in patients 
treated for osteoporosis and 5 in patients treated for Paget 
Disease, which represents less than 5% of all osteonecrosis 
cases published worldwide.  
Treatment duration is also a relevant factor.  In general 
exposure to the drug is usually prolonged (from 9 to 14 
months), although cases have been seen following short 
periods of  treatment (4 months).  On the other hand, 
the existence of repeated traumatism to the oral mucous 
membrane or dentoalveolar surgery to treat dental infec-
tions difficult to resolve in another manner also seem to 
influence the development of this process (5,6,12,23). 
Finally, smokers, diabetic patients or those with periferic 
vascular diseases, as well as those who receive concomitant 
treatments with corticosteroids, antineoplasics (thalidomide, 
Bortezomib…) must be evaluated in greater detail (12, 23).
Marx et al (24) recently talk about a risk factor which may 
change our outcome in oral surgery: the morning serum 
values of CTX terminal telopeptide. If this value is less than 
100 pg/ml, osteoncrosis risk is high; if between 100-150 pg/
ml, risk is medium.If the value is over 150, risk is low.
Results and Discussion
During the growth period, the skeleton experiences a series 
of changes that lead to a progressive increase in bone thic-
kness and length (“bone modeling”).  Furthermore, once 
development has finished, the skeleton does not remain 
inert, rather it continues renewing itself, although without 
perceiveable changes in its shape or size.  This continuous 
renovation process is known as osseous remodeling, and 
it is carried out through the destruction by osteoclasts of 
small microscopic tissue units, scattered throughout the 
skeletion, which are subsequently replaced by new tissue 
formed by the osteoblasts.  The referred units are known 
by the name of bone remodeling units, BRU, and they are 
integrated by osteoclasts, osteoblasts, along with the cells 
derived from the latter (osteocytes) and other accessory 
cells of uncertain significance.  The difference between the 
amount of bone that is destroyed and that whcih is formed 
in each of the BRU is known as “osseous balance”(7). 
Under normal conditions, it value is zero until the age of 
30-40 years, but from this age, there is a slight negative 
balance of approximately 3%, which explains the bone 
mass loss produced with ageing and osteoporosis (Figure 
3). The speed of osseous renovation, that is to say, the 
volume of renewed bone in a time unit, is known by the 
term “replacement” or “bone turnover” (13). 
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Bisphosphonates bind avidly to hydroxyapatite crystals situa-
ted in osseous surfaces, especially in areas of active remode-
lling and they remain bound to the skeleton during prolonged 
periods of time, since they are not susceptible to enzimatic 
degradation by osseous pyrophosphatases.  From here they 
are released and internalized by osteoclasts, in which they 
provoke a decrease in resorptive activity and therefore in bone 
turnover.  Prolonged treatment with these drugs may cause 
excessive suppression of remodeling (the so-called “frozen 
bone”), which determines a reduction in the normal pheno-
mena of bone repair, which would favor the accumulation of 
microlesions in the skeleton and the consequent appearance 
of areas of osteonecrosis (5) (Figure 3).
In a review of the 368 cases of osteochemionecrosis fo-
llowing continuous administration of bisphosphonates, 
published by various authors up to May 2006, 46.5% 
had prior diagnosis of multiple myeloma, 38.8% was pa-
tients with metastatic breast cancer; 6.2% of matastatic 
prostate cnacer; 4.1% suffered from osteoporosis; 3.5% 
other metastatic diseases and 0.8% was diagnosed with 
Paget disease (3).
The drugs that produce the greatest incidence of osteoche-
monecrosis are:  zoledronate, pamidronate, alendronate, 
alendronate, risendronate and ibandronate, from greatest 
to least (23).
The risk of osteonecrosis being produced is cumulative, 
and it may reach 21% in the third year of intravenous 
bisphosphonate use (3, 23).
Marx (6) and Migliorati (2) suggest that biphosphonates 
are directly responsible for the osteochemionecrosis in 
their patients.  For Bagan (14) the patients take many 
contributing drugs in the cases that they present:  ta-
moxyfene, cyclophophamide, 5-fluorosfarnide, adriami-
cine, thalidomide.....
For Marx (6) 77 % of their cases appear following exo-
doncies, likewise for 70 % of Bagán’s cases (14), for the 
remainder this is not true.  39% of the cases presented by 
Farrugia et al. had a prior dental treatment (13). Pastor 
(15) relate in their 3 documented cases prior dental ex-
traction.  Melo (9) describe it as an antecednet in most 
of their 11 cases.
In general, there is 60% incidence in mandibula, 30% in 
upper jaw and the remainder in both (3, 23).
For Hansen (10) there are more cases in men, while for 
Marx (6) the 3:2 ratio favors women. 
The risk of  suffering osteochemionecrosis in patients 
who take oral aminobisphosphonates (for example, alen-
dronate), after undergoing a dental treatment such as 
exodoncy, implants or periodoncy is unknown, although 
there are very few described cases.  Gonzalez Moles et al 
(21) describe ulcerations in the oral mucous membranas 
of patients treated with oral bisphosphonates in osteopo-
rosis treatment. Starck (16) describe a case of mandibular 
osteonecrosis in a patient treated with aminobisphos-
phonates due to her osteoporosis, following the fitting of 
oseointegrated implants.  On the other hand, according 
to a study by Narai (17) following the administration of 
alendronate to rats with induced osteoporosis and then 
fitting them with implants, the removal torque increased 
significantly.  
Bone remodeling and resorption play an important role 
in normal bone homeostasis.  When osteoclastic action 
begins, there is a release of cytokines and growth factors 
toward essential osseous matriz which are essential for 
maturing of new bone.  Inhibition of new bone formation 
may affect bone quality during growth and the healing 
of  fractures.  Cases of  children’s bones in growth are 
documented with a great degree of esclerosis in the meta-
Fig. 3. Normal and osteoporotic bone and gold standar of bone mass with the age.
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fisaria area (osteopetrosis) after receiving bisphosphonate 
treatment for 2 years (18,19,20).  
Some cytokines activate resorption and during this process 
some substances are released that are buried in bone matrix 
(growth factors) that carry out an important role in the 
“hook” process.  On the other hand, it is not demonstrated 
that treatment with BP delays the consolidation of frac-
tures, at least in adults.  Furthermore, from the outset BP 
treatment is counter-indicated in children, because of this 
and other actions (18,19,20).
Pamidronate and many other bisphosphonates have been 
associated following IV administration with an acute 
reaction phase with fever, (pseudogripal symptoms which 
have not been given importance), and the release of va-
rious cytokines such as interleukine 6, TNF -α. reactive 
C protein and elastase (5).
- Preventive recommendations
In June 2004 a panel of experts proposed a series of re-
commendations for handling patients with osteochemio-
necrosis of the jaws treated with aminobisphosphonates 
(3).  Patients were classified into three groups:
1.-Those that are going to begin therapy.  Here patients 
with osteoporosis treated with oral alendronate type ami-
nobisphosphonates are included. 
2.- Patients without osteonecrosis in aminobisphospho-
nate therapy. 
3.- Patients with osteochemionecrosis. 
The preventive treatment that must be given to each group 
of patients is shown in Table 2 and it is the same one that 
is received by patients who are going to undergo radiation 
to the head and neck, as well as those who are going to 
have a bone marrow transplant (23,24,25,26).
Handling patients with osteochemionecrosis established 
in the jaws is very complex.  Surgical debridement is not 
effective and may even enlarge the lesions.  There are no se-
curity margins of viable bleeding bone as in the treatment 
of osteoradionecrosis (5,9). Neither has therapy with hy-
perbaric oxygen been effective.  When bone is left exposed 
vinyl pluggers may be adapted to cover it, while taking into 
account that they themselves may microtaumatize the soft 
tissue and aggravate the situation (2).
The best option seems to be rather long term therapy 
with systematic antibiotics, (penicillins with clavulanic 
acid, metronidazol, doxicycline in allergic patients and 
clyndamicine) and 0.12% chlorhexidine rinses, 3 or 4 times 
a day, according to all authors consulted (2,3,5,8,9,23). 
Follow-up every 2 or 3 weeks to evaluate the lack of 
supperation or pain is necessary, although in many cases 
the lack of healing or mucosa closing is confirmed.The 
most aggressive surgical treatment  is not well approved 
now and, physicians  better survey the oral lesions and go 
wih the conservative measures (23,24).
The patient must be informed of the risk of any oral ope-
ration if  he is going to treated long term with aminobis-
phosphonates, and he must weigh the pros and cons with 
the internist, the oncologist and the odontologist (2).
There is a wide ranging discussion on whether or not to 
suspend bisphosphonate therapy once lesions have been pro-
duced (2,3,13,15). The motive is the long bone permanence 
of the drugs, even years later.  On the other hand, if they are 
suspended, the antiangiogenic effect ceases and they could 
improve soft tissues and periostio. Marx (6) recommends 
suspending the therapy for 2 months and continuing the 
oral hygene measures, antibiotics and oral lesion follow-up 
every 3-4 months. However, the same author recently  (24) 
talk about “therapeutic holidays” of bisphosphonates during 
6-9 months in order to recover CTX values  out of 25,9 pg/
ml each month ,and cross the risk area.
There is controversy regarding oseointegrated implants, 
and much shortage of studies, but in general, it is recom-
mended to avoid them as any other surgical procedure. 
Patients treated with alendronate or any other oral ami-
nobisphosphonate must also be warned of the risks, but 
this should be done by telling them that there are very few 
cases described of osteochemionecrosis in oral treatments, 
which is probable due to the low doses and slight potency. 
Patients                                                            Treatments
Group1
Treat active oral infections, impacted teeth, Eliminate teeth not able to be restaured and 
periodontal one with bad prognose. Dental appointments/ 6 months.2 prophylax /year. 
Endodontics and caries treatment.
Group 2
< 3 months of therapy:= treatment than group 1 
>3 months of therapy: avoid surgical procedures (endodontics, scaling and 
debridgement).Administrate systemic antibiotics. Simple dentalextraction with small 
bone manipulation  and survey until  healing.
Group 3
= as group 2 with > 3 months of therapy .Diagnose with CT .Necrotic bone extirpation 
with small trauma .Clorhexidine 0, 12%. Or mouthrinse with H202.Antibiotics in 
monotherapy or combined. Analgesics .Soft layer on oral prótesis until improvement. 
Table 2. Purpouses of preventive measures for patients treated with aminobisphosphonates  (10).
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If  there are already implants, it is adviseable to carry out 
close follow-up and, and if  it wer to occur, dismantle the 
protetic stucture and leave the implants submerged (1).
Wearers of removable prosthesis must be warned of the 
risks, with the elimination of fin edges and by adapting a 
tissue conditioner to their inner side (1,2,6,8,9).
Conclusions
Although incidence is very low in comparison with the 
millions of treatments prescribed worldwide, osteonecrosis 
of the jaws constitutes a new complication described in 
patients treated with bisphosphonates.  Most of the cases 
develop in patients with multiple myeloma or metastastic 
cancers who receive intraveneous treatment with amino-
bisphosphonates, although there have also been described 
isolated cases in osteoporotic women treated with oral 
BP.  Preventive odontological treatments must be applied 
before and during therapy with these drugs, and in gene-
ral, they must be suspended during a time if  lesions are 
produced until there is improvement in the process, even 
by considering other therapeutic alternatives.  
There still remain many doubts to resolve regarding the 
subject.  In clinical trials carried out with aminobisphos-
phonates, it has been confirmed that these drugs are 
effective in reducing osteoporotic fractures, and among 
the adverse reactions, the incidence of osteonecrosis was 
minimal or nonexistent.  Even with ibandronate IV, the 
latest to appear, cases of osteonecrosis were not observed 
in the trials published to date.  In fact, the secondary effects 
ofserved in clinical trials are those in the techinical descrip-
tion sheets of the drugs before their commercialization. 
Something else is that these consequences may have been 
observed in habitual clinical practice after carrying out 
a great number of treatments worldwide.  Due to this, 
it is advisable to publish bibliographical reviews of the 
casuistry that may appear.  
A task force is being organizad in the Association for 
Bone and Minderal Research (ASBMR) to aid scientists, 
doctors, dentists and oral surgeons in their treatment and 
recommendations to patients who take bisphosphonates 
for the treatment of osteoporosis or Paget disease. 
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